Compare Incyte Corporation (INCY) vs First Trust NASDAQ 100 Technology Index Fund (QTEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs First Trust NASDAQ 100 Technology Index Fund — how do they compare? Incyte Corporation trades at $112.8 (market cap $22.85B), while First Trust NASDAQ 100 Technology Index Fund trades at $333 (market cap $4.10B). The key difference: Incyte Corporation is far larger — about 5.6× First Trust NASDAQ 100 Technology Index Fund's market cap, and First Trust NASDAQ 100 Technology Index Fund is trading nearer its 52-week high, Incyte Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and First Trust NASDAQ 100 Technology Index Fund for 40 Days on average.
| INCY | QTEC | |
|---|---|---|
Market Cap | $22.85B | $4.10B |
Volume | 1,927,029 | 264,303 |
Sector | Health | Broad Market / Factor |
52-Week High | $129.93 | $340.28 |
52-Week Low | $83.80 | $207.03 |
Typical Hold Time | 33 Days | 40 Days |
Enterprise Value | $18.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.44, up 0.63% with a bullish technical outlook despite mixed moving average signals. The company shows strong fundamentals with $5.14B revenue, 27.71% net margin, and robust cash flow of $1.41B. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI position the company for growth, with analysts projecting $5.8B revenue and $1.6B net income for 2026.
The investment case centers on Incyte's successful diversification strategy and strong profitability metrics, though investors face risks from JAKAFI patent expiration in 2029 and near-term earnings volatility. With 52% analyst buy ratings and a $132.43 consensus price target representing 17% upside, the stock offers growth potential but requires monitoring of pipeline execution.
QTEC, the First Trust NASDAQ-100-Technology Sector ETF, trades at $335.82, down 1.31% on the day. Technical indicators show a bullish trend from moving averages but caution from overbought RSI levels. The ETF provides equal-weighted exposure to the technology sector, with recent analysis highlighting its broader sector definition and liquidity advantages.
The outlook for QTEC is supported by bullish technical trends and its role in tech exposure, though overbought conditions and sector volatility present risks. Investment opportunity lies in diversified tech access, but investors face market sensitivity and valuation pressures inherent to technology stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About First Trust NASDAQ 100 Technology Index Fund
QTEC is an ETF that seeks to track the performance of the NASDAQ-100 Technology Sector Index. The fund provides targeted exposure to companies within the NASDAQ-100 that are classified as technology or telecommunications companies, focusing on firms involved in software, hardware, and related services. QTEC is a tool for investors seeking focused exposure to high-growth, large-cap technology companies listed on the NASDAQ exchange.
Read more on QTEC →
